HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodriguez, M. Articles by Lennon, V. A. Search for Related Content PubMed PubMed Citation Articles by Rodriguez, M. Articles by Lennon, V. A.

Immunoglobulins reactive with myelin basic protein promote CNS remyelination

From the Departments of Neurology (Drs. Rodriguez and Lennon), Immunology (Drs. Rodriguez, Miller, and Lennon), and Laboratory Medicine and Pathology (Dr. Lennon), Mayo Medical School, Rochester, MN.
Supported by research grants NS 24180 from the National Institutes of Health, and RG 1878-B1 and RG 2174-A-3 from the National Multiple Sclerosis Society, and the C.T. Fernie Fund.
Received March 10, 1995 Accepted in final form April 26, 1995.
Address correspondence and reprint requests to Dr. Moses Rodriguez, Department of Immunology, Mayo Clinic/Foundation, Rochester, MN 55905.

We tested the hypothesis that immunoglobulins directed against a CNS autoantigen, myelin basic protein, may promote remyelination in the course of a chronic, immune-mediated demyelinating disease SJL/J mice infected chronically with Daniel's strain of Theiler's virus served as an experimental model of MS. The spinal cords of these mice exhibit extensive primary demyelination and inflammation with minimal spontaneous remyelination. Treatment with whole antiserum or affinity-purified mouse immunoglobulins directed against rat or rabbit myelin basic protein increased new myelin synthesis as measured by quantitative morphometry. Electron microscopy revealed numerous oligodendrocytes in remyelinated CNS lesions and a relative lack of inflammatory cells. Viral antigen persisted in the spinal cord despite enhanced CNS-type remyelination. These findings indicate that immunoglobulins reactive with myelin autoantigens have the potential to promote myelin repair.

NEUROLOGY 1996;46: 538-545

This article has been cited by other articles:

				D. Pohlau, H. Przuntek, M. Sailer, F. Bethke, J. Koehler, N. Konig, C. Heesen, P. Spath, and I. Andresen Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study Multiple Sclerosis, November 1, 2007; 13(9): 1107 - 1117. [Abstract] [PDF]

				F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]

				J. H. Noseworthy, P. C. O'Brien, T. M. Petterson, J. Weis, L. Stevens, W. K. Peterson, D. Sneve, S. A. Cross, J. A. Leavitt, R. G. Auger, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis Neurology, June 12, 2001; 56(11): 1514 - 1522. [Abstract] [Full Text] [PDF]

				J. H. Noseworthy, P. C. O'Brien, B. G. Weinshenker, J. A. Weis, T. M. Petterson, B. J. Erickson, A. J. Windebank, J. P. Whisnant, K. A. Stolp-Smith, C. M. Harper Jr., et al. IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial Neurology, October 24, 2000; 55(8): 1135 - 1143. [Abstract] [Full Text] [PDF]

				M. Stangel, F. Boegner, C. H Klatt, C. Hofmeister, and S. Seyfert Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, January 1, 2000; 68(1): 89 - 92. [Abstract] [Full Text]

				S. Mata, F. Lolli, M. Soderstrom, F. Pinto, and H. Link Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD I a Multiple Sclerosis, December 1, 1999; 5(6): 379 - 388. [Abstract] [PDF]

				R. J.M. Franklin Review : Remyelination--A Regenerative Process in the CNS Neuroscientist, May 1, 1999; 5(3): 184 - 191. [Abstract] [PDF]

				P. F Smith and C. L Darlington Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120. [Abstract] [PDF]

				D. Mcgavern, K. Asakura, and M. Rodriquez Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis? Neuroscientist, January 1, 1999; 5(1): 19 - 28. [Abstract] [PDF]

				K. Asakura, D. J. Miller, L. R. Pease, and M. Rodriguez Targeting of IgMkappa Antibodies to Oligodendrocytes Promotes CNS Remyelination J. Neurosci., October 1, 1998; 18(19): 7700 - 7708. [Abstract] [Full Text] [PDF]

				K Asakura and M Rodriguez A unique population of circulating autoantibodies promotes central nervous system remyelination Multiple Sclerosis, June 1, 1998; 4(3): 217 - 221. [Abstract] [PDF]

				G. S Francis, M. S Freedman, and J. P Antel Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study Multiple Sclerosis, December 1, 1997; 3(6): 370 - 376. [Abstract] [PDF]

				F. Fazekas, F. Deisenhammer, S. Strasser-Fuchs, G. Nahler, and B. Mamoli for the Au Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study Multiple Sclerosis, April 1, 1997; 3(2): 137 - 141. [Abstract] [PDF]